Ann: First Patient Enrolled - Clinical Trial for Cancer Treatment, page-17

People are waiting to see that the FDA approval on Bronchitol actually translates into a slowing of cash-burn (and god-forbid even a profit). I know Gary has suggested that it will, but Gary's word is worth about the same as a sack of potatoes based on what he has promised but not delivered in the past. The upcoming quarterly (end of April) will be interesting to get the first view on the changing revenue:cost profile of the mannitol business. If Bronchitol gets some traction its a game-changer for Pharmaxis, if not, 8c is about the right valuation.